This week saw major AI advances in healthcare. The U.S. FDA completed its agency-wide AI rollout on June 30, allowing scientists to dramatically speed up drug reviews by automating tedious tasks. FDA Commissioner Dr. Martin Makary called this a game-changer technology.

Meanwhile, experts confirmed that intelligent agents are now actively transforming healthcare through next-gen diagnostics and predictive drug discovery. The AI medical diagnostics market is projected to hit $46.59 billion by 2034, with private equity investing heavily in companies like Tempus AI and Recursion Pharmaceuticals.

These developments show AI moving from pilots to real-world impact, accelerating treatments while raising questions about workforce changes and data bias.